Impact of Age on Treatment Patterns and Outcomes in Patients With Non‐Metastatic Castration‐Resistant Prostate Cancer
- 24 December 2025
- journal article
- Published by Wiley in International Journal of Urology
- Vol. 33 (1)
Abstract
Objectives: To evaluate the impact of age on treatment patterns and outcomes in patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). Methods: We conducted a retrospective multicenter analysis of 428 patients with nmCRPC from 25 tertiary centers (2002–2022). Patients were divided into two age groups: < 80 and ≥ 80 years. The outcomes included cancer‐specific survival (CSS), overall survival (OS), and progression‐free survival (PFS). Results: Among 428 patients (median follow‐up, 32.5 months), performance status (PS) 0 was more frequent in < 80 vs. ≥ 80 years (78% vs. 58%, p < 0.001). Use of first‐line androgen receptor signaling inhibitors (ARSIs) was similar (58% vs. 59%, p = 0.83) among all, whereas any‐line docetaxel use was less common in patients aged ≥ 80 years (33% vs. 9% for < 80 vs. ≥ 80, p < 0.001). Five‐year CSS was 76.5% vs. 63.7% ( p = 0.002) and five‐year OS 73.8% vs. 59.9% ( p = 0.006) for < 80 vs. ≥ 80 years, respectively. Time‐to‐treatment failure was shorter in patients aged ≥ 80 years ( p = 0.04). Conclusion: Maintaining PS and managing ARSI‐related adverse events are essential in older patients with nmCRPC and may preserve their eligibility for chemotherapy and improve their prognosis.Keywords
This publication has 20 references indexed in Scilit:
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2024
- Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsThe Lancet Oncology, 2021
- Impact of age at diagnosis of de novo metastatic prostate cancer on survivalCancer, 2019
- Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopeniaProstate Cancer and Prostatic Diseases, 2019
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerNew England Journal of Medicine, 2018
- Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysisClinical Genitourinary Cancer, 2018
- Apalutamide Treatment and Metastasis-free Survival in Prostate CancerNew England Journal of Medicine, 2018
- Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu studyJournal of Cancer Research and Clinical Oncology, 2018
- A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical ImplicationsEuropean Urology, 2014
- Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate CancerEuropean Urology, 2009